Published: Sat, March 04, 2017
Medical | By Ismael Lynch

Kite Pharma Inc (KITE) Rating Lowered to Hold at Stifel Nicolaus


Kite Pharma, Inc. (NASDAQ:KITE) has a current PEG Ratio of 0.00. They now have a United States dollars 46 price target on the stock.

Kite Pharma (NASDAQ:KITE) last issued its quarterly earnings results on Monday, February 27th.

In the trailing 12 months period, return on assets ratio of the Company was -33.80% and return on equity ratio was -39.30% while its return on investment ratio was -16.80%.

Kite said it planned to submit a marketing application for the therapy with European regulators this year. During the same quarter in the prior year, the business earned ($0.54) earnings per share.

02/01/2017 - Wedbush began new coverage on Kite Pharma, Inc. giving the company a " rating. If you are reading this story on another domain, it was illegally copied and republished in violation of USA & global copyright & trademark laws. The legal version of this report can be viewed at https://www.com-unik.info/2017/03/03/fbr-co-comments-on-kite-pharma-incs-q3-2017-earnings-kite.html.

"The numbers are fantastic", said Dr. Fred Locke, a blood cancer expert at Moffitt Cancer Center in Tampa who co-led the study and has been a paid adviser to Kite.

Kite Pharma, Inc. on 11/09/2016 reported its EPS as $-1.49 with the analysts projecting the EPS of the stock as $-1.62. HC Wainwright reissued a "buy" rating and issued a $78.00 target price on shares of Kite Pharma in a research report on Wednesday, December 7th. Citigroup issued rating on the stock of Kite Pharma Inc (NASDAQ:KITE) in a research note issued to investors on Mar-02-17, the stock received "Downgrade" rating from Buy to Neutral. The analysts believe that the company stock price could grow as high as $88.

Reliable stocks in today's share market: Marathon Oil Corporation (NYSE:MRO)
The company reported $0.43 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.26 by $0.17. Susquehanna Bancshares Inc reaffirmed a "neutral" rating on shares of Marathon Oil in a report on Wednesday, December 7th.

Justice Department withdraws Obama-era challenge to Texas voter ID law
District Judge Nelva Gonzales Ramos to dismiss their claim that Texas acted with discriminatory intent during a hearing Tuesday. A hearing in the case was scheduled for Tuesday in federal court in Texas.

Microsoft Bringing Mixed Reality To The Xbox
Terry Myerson, the Windows and Devices Group chief at Microsoft says there is a reason the words Mixed Reality are incorporated. Microsoft's dev kits are targeted at game developers, because to Microsoft that's exactly what these headsets are for.

Shares of Kite Pharma (NASDAQ:KITE) opened at 75.10 on Friday. The company's price sits 45.89% above from its 50-day moving average of $52.75 and 44.23% far from the stock's 200-day moving average which is $52.23. Kite Pharma Inc has a 52 week low of $39.82 and a 52 week high of $80.82. Out of 13 analysts polled by TipRanks in the last 3 months, 9 are bullish on Kite stock and 4 remain sidelined.

Institutional investors have recently added to or reduced their stakes in the stock.

In other Kite Pharma news, COO Cynthia M. Butitta sold 2,482 shares of the stock in a transaction dated Tuesday, December 20th. Vanguard Group Inc. now owns 2,935,406 shares of the biopharmaceutical company's stock valued at $146,771,000 after buying an additional 173,879 shares in the last quarter.

01/06/2017 - Kite Pharma, Inc. had its "outperform" rating reiterated by analysts at FBR Capital Markets. The company's stock had a trading volume of 257,429 shares. Finally, RBC Capital Markets restated a "buy" rating on shares of Kite Pharma in a report on Thursday, November 24th. BlackRock Fund Advisors now owns 1,751,216 shares of the biopharmaceutical company's stock valued at $97,823,000 after buying an additional 94,421 shares in the last quarter. The stock was sold at an average price of $50.86, for a total transaction of $249,264.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

The Stock had a 1.27 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.3 and 1.33 respectively. Following the completion of the sale, the senior vice president now directly owns 17,311 shares of the company's stock, valued at approximately $878,706.36. The disclosure for this sale can be found here. In the last quarter, insiders sold 170,862 shares of company stock worth $11,322,241.

A number of drugmakers, including Juno Therapeutics Inc, Novartis AG and Bluebird Bio Inc, are testing vehicle T-cell therapies in various stages of development.

Like this: